US Patent

US9827197 — Diclofenac formulations and methods of use

Formulation · Assigned to APR Applied Pharma Research SA · Expires 2026-06-16 · 0y remaining

Vulnerability score 60/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects formulations and methods for treating migraine and acute pain using diclofenac.

USPTO Abstract

Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.

Drugs covered by this patent

diclofenac-potassium (DICLOFENAC POTASSIUM)

Patent Metadata

Patent number: US9827197
Jurisdiction: US
Classification: Formulation
Expires: 2026-06-16
Drug substance claim: No
Drug product claim: Yes
Assignee: APR Applied Pharma Research SA
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.